SAN LEANDRO, Calif., Sept. 2, 2022 (GLOBE NEWSWIRE) -- Nanōmix Corporation (OTCQB: NNMX) (“Nanōmix” or the “Company”), a leader in the development of mobile, affordable, point-of-care diagnostics, today announced an agreement with Mobility Health, whereby Nanōmix and Mobility Health plan to collaborate in the development of an LDT (Lab Developed Test) that can be deployed in a fully mobile lab to evaluate levels of circulating antibodies to COVID-19. Nanōmix plans to supply the product elements and Mobility Health plans to complete development and validation of the test, with plans to file for a CLIA Lab Emergency Use Authorization (EUA) with the FDA.
Mobility Health founder and CEO, Sandra Gunselman, said, “Nanōmix’s affordable, point-of-care technology will be used to offer patients a timely, highly accurate status of their protection against COVID-19 and allow them to make informed decisions in consultation with their medical providers. This offering fits extremely well with our mobile laboratory platform, while advancing our mission of providing innovative new products in the enduring fight against COVID-19 and other infectious diseases.”
Dr. Thomas Schlumpberger, Nanōmix CEO, said, “We share Mobility Health’s mission to transform community healthcare through increased accessibility to healthcare testing and services. We believe our eLab system is the ideal mobile platform to provide rapid testing of COVID-19 antibodies, as well as many other future indications.”
The Nanōmix eLab® system is a mobile, hand-held immunoassay and chemistry diagnostic system designed for the needs of rapid point-of-care testing. The Nanōmix eLab® system offers a variety of benefits, including results in minutes, lower cost, and portability, while providing accurate, quantitative results comparable in quality to those provided by central lab testing. Furthermore, the company has recently introduced the S1 Panel Cartridge as an aid in rapidly diagnosing critical infections including sepsis. The panel provides quantitative test results for procalcitonin (PCT), C-reactive protein (CRP) and lactate (LAC) from a single venous whole blood or plasma sample type. The assay runs on the eLab Analyzer with results available in approximately 12 minutes from sample to answer, versus the current diagnostic solutions, which can take hours to provide a test result. The S1 Panel assay has received CE marking in Europe and has UK Medicines and Healthcare products Regulatory Agency (MHRA) registration.
Mobility Health is a biohealth diagnostic company focused on providing accurate, rapid testing of infectious diseases to protect population health and safety. Mobility Health was established with a mission to transform community-based healthcare by deploying new technologies that eliminate barriers to rapid, advanced molecular testing and healthcare services. Founded in 2020 by Sandra Gunselman, Ph.D., a molecular biology and laboratory operations expert with a passion for reaching patients in need, the company combines cutting-edge laboratory technologies with mobile capabilities to offer unique services to underserved communities. For more information, visit www.mobilityhealthlab.com
Nanōmix (OTCQB: NNMX) is developing mobile point-of-care diagnostics with its Nanōmix eLab® System platform and assays that provide rapid, accurate, quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The company’s products are designed to broadly impact healthcare delivery by bringing diagnostics to the point of initial patient interaction, whether in the hospital or in pre-hospital, remote or alternate-care settings, thereby enabling faster clinical decision-making and potentially treatment-in-place. Nanomix’s first assays address the need for faster diagnosis of critical infections including sepsis. The company is developing a pipeline of other tests designed to improve patient outcomes by making high-quality diagnostic information available within minutes. For more information, visit www.nanomixdx.com.
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Forward looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company’s ongoing and planned product development; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext.304